Featured Research

from universities, journals, and other organizations

Heart Device: Novel Patent Foramen Ovale Closure System Safe And Effective, Study Suggests

Date:
May 15, 2009
Source:
Society for Cardiovascular Angiography and Interventions
Summary:
A new device designed to close a common heart defect known as a patent foramen ovale is safe and effective at 90-days follow up, according to a new study.

A new device designed to close a common heart defect known as a patent foramen ovale (PFO) is safe and effective at 90-days follow up, according to a new study released May 8 at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions in Las Vegas.

PFO is a common condition in which a hole that connects the two upper chambers of the heart (atria) during fetal development fails to close properly after birth. About 25 percent of the general population has PFO, which is associated with an increased risk of stroke. PFO may also be associated with migraines and decompression illness in divers.

The FlatStent EF, developed by Coherex Medical,Inc., is unique because it is implanted within the PFO tunnel, leaving a minimal amount of the device exposed to circulation, which could reduce the risk of blood clots. The mechanism of action of the FlatStent EF should limit the incidence of other major complications associated with septal patching devices currently in use, such as erosion, persistent arrhythmia, and valve apparatus distortion.

In the study, 29 of 41 patients (70.7%) who received the FlatStent EF™ PFO Closure System had complete PFO closure immediately following implantation. After 90 days, 17 of 19 patients (89%) had complete or clinical closure. The remaining 22 patients had not yet completed the 90-day follow up exam.

"The FlatStent is designed to be safer and easier to use than current PFO closure systems," said Horst Sievert, MD, professor of internal medicine, cardiology and vascular medicine at the Cardiovascular Center in Frankfurt, Germany, and the study's principal investigator. "Given the number of patients living with PFO, the results of this study show promise in providing additional treatment options that could help prevent stroke and other conditions associated with PFO."

In the study, no device-related complications were reported. The 100-patient, multicenter registry study is designed to evaluate 30, 90 and 180-day safety and performance.


Story Source:

The above story is based on materials provided by Society for Cardiovascular Angiography and Interventions. Note: Materials may be edited for content and length.


Cite This Page:

Society for Cardiovascular Angiography and Interventions. "Heart Device: Novel Patent Foramen Ovale Closure System Safe And Effective, Study Suggests." ScienceDaily. ScienceDaily, 15 May 2009. <www.sciencedaily.com/releases/2009/05/090508134949.htm>.
Society for Cardiovascular Angiography and Interventions. (2009, May 15). Heart Device: Novel Patent Foramen Ovale Closure System Safe And Effective, Study Suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/05/090508134949.htm
Society for Cardiovascular Angiography and Interventions. "Heart Device: Novel Patent Foramen Ovale Closure System Safe And Effective, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/05/090508134949.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins